Patents by Inventor Randall C. Schatzman

Randall C. Schatzman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTAGONISTS OF IL-6 TO PREVENT OR TREAT CACHEXIA, WEAKNESS, FATIGUE, AND/OR FEVER
    Publication number: 20210107975
    Abstract: The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
    Type: Application
    Filed: March 18, 2020
    Publication date: April 15, 2021
    Inventors: JEFFREY T.L. SMITH, RANDALL C. SCHATZMAN, MARK LITTON, JOHN LATHAM
  • ANTAGONISTS OF IL-6 TO PREVENT OR TREAT CACHEXIA, WEAKNESS, FATIGUE, AND/OR FEVER
    Publication number: 20190270805
    Abstract: The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
    Type: Application
    Filed: November 15, 2018
    Publication date: September 5, 2019
    Inventors: JEFFREY T.L. SMITH, RANDALL C. SCHATZMAN, MARK LITTON, JOHN LATHAM
  • ANTIBODIES TO IL-6 AND USE THEREOF
    Publication number: 20190083665
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.
    Type: Application
    Filed: October 1, 2018
    Publication date: March 21, 2019
    Inventors: Leon F. Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Olson Anderson, Benjamin H. Dutzar, John A. Latham, Brian R. Kovacevich, Jeffrey T.L. Smith, Mark Litton, Randall C. Schatzman
  • Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
    Patent number: 10160804
    Abstract: The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: December 25, 2018
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Jeffrey T. L. Smith, Randall C. Schatzman, Mark Litton, John Latham
  • Methods of aiding in the diagnosis of diseases using anti-IL-6 antibodies
    Patent number: 10117955
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: November 6, 2018
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Leon Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Olson Anderson, Benjamin H. Dutzar, John A. Latham, Brian R. Kovacevich, Jeffrey T. L. Smith, Mark Litton, Randall C. Schatzman
  • ANTAGONISTS OF IL-6 TO PREVENT OR TREAT CACHEXIA, WEAKNESS, FATIGUE, AND/OR FEVER
    Publication number: 20170198036
    Abstract: The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
    Type: Application
    Filed: December 15, 2016
    Publication date: July 13, 2017
    Inventors: Jeffrey T.L. SMITH, Randall C. Schatzman, Mark Litton, John Latham
  • ANTIBODIES TO IL-6 AND USE THEREOF
    Publication number: 20170115307
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.
    Type: Application
    Filed: September 26, 2016
    Publication date: April 27, 2017
    Inventors: Leon Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Olson Anderson, Benjamin H. Dutzar, John A. Latham, Brian R. Kovacevich, Jeffrey T.L. Smith, Mark Litton, Randall C. Schatzman
  • Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
    Patent number: 9546213
    Abstract: The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
    Type: Grant
    Filed: March 14, 2011
    Date of Patent: January 17, 2017
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Jeffrey T. L. Smith, Randall C. Schatzman, Mark J. Litton, John Latham
  • ANTAGONISTS OF IL-6 TO PREVENT OR TREAT CACHEXIA, WEAKNESS, FATIGUE, AND/OR FEVER
    Publication number: 20110217303
    Abstract: The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
    Type: Application
    Filed: March 14, 2011
    Publication date: September 8, 2011
    Inventors: Jeffrey T.L. Smith, Randall C. Schatzman, Mark J. Litton, John Latham
  • Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
    Patent number: 7906117
    Abstract: The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
    Type: Grant
    Filed: November 25, 2008
    Date of Patent: March 15, 2011
    Assignee: AlderBio Holdings LLC
    Inventors: Jeffrey T. L. Smith, Randall C. Schatzman, Mark J. Litton, John Latham
  • Antagonists of IL-6 to prevent or treat Cachexia, weakness, fatigue, and/or fever
    Publication number: 20090291077
    Abstract: The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
    Type: Application
    Filed: November 25, 2008
    Publication date: November 26, 2009
    Inventors: Jeffrey T.L. Smith, Randall C. Schatzman, Mark J. Litton, John Latham
  • Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases
    Patent number: 7374892
    Abstract: Methods and compositions are provided for the diagnosis and treatment of iron overload diseases and iron deficiency diseases.
    Type: Grant
    Filed: August 8, 2006
    Date of Patent: May 20, 2008
    Assignees: Bio-Rad Laboratories, Inc., California Institute of Technology
    Inventors: John N. Feder, Pamela J. Bjorkman, Randall C. Schatzman
  • Methods and compositions for diagnosis and treatment of iron misregulation diseases
    Patent number: 7374765
    Abstract: Methods and compositions are provided for the diagnosis and treatment of iron misregulation diseases, including HFE polypeptides, agonists, and antagonists, and transferrin receptor agonists and antagonists.
    Type: Grant
    Filed: October 1, 2004
    Date of Patent: May 20, 2008
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: John N. Feder, Randall C. Schatzman, Zenta Tsuchihashi
  • Peptides and peptide analogues designed from HFE protein and their uses in the treatment of iron overload diseases
    Patent number: 7329650
    Abstract: The present invention relates to peptides and peptide analogues designed from HFE protein. In particular, it relates to peptides and peptide analogues designed from an alpha-1 region of HFE protein which lowers the binding affinity of transferrin receptor for transferrin. Such compounds mimic HFE protein function, and reduce iron uptake and/or accumulation by a cell.
    Type: Grant
    Filed: July 18, 2005
    Date of Patent: February 12, 2008
    Assignees: Bio-Rad Laboratories, Inc., California Institute of Technology
    Inventors: John N. Feder, Randall C. Schatzman, Pamela J. Bjorkman, Melanie Bennett, Jose Lebron
  • Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases
    Patent number: 7119170
    Abstract: Methods and compositions are provided for the diagnosis and treatment of iron overload diseases and iron deficiency diseases.
    Type: Grant
    Filed: March 4, 2002
    Date of Patent: October 10, 2006
    Assignees: Bio-Rad Laboratories, Inc, California Institute of Technology
    Inventors: John N. Feder, Pamela J. Bjorkman, Randall C. Schatzman
  • Peptides and peptide analogues designed from HFE protein and their uses in the treatment of iron overload diseases
    Patent number: 6924265
    Abstract: The present invention relates to peptides and peptide analogues designed from HFE protein. In particular, it relates to peptides and peptide analogues designed from an alpha-1 region of HFE protein which lowers the binding affinity of transferrin receptor for transferrin. Such compounds mimic HFE protein function, and reduce iron uptake and/or accumulation by a cell.
    Type: Grant
    Filed: July 9, 2001
    Date of Patent: August 2, 2005
    Assignees: Bio-Rad Laboratories, Inc., California Institute of Technology
    Inventors: John N. Feder, Randall C. Schatzman, Pamela J. Bjorkman, Melanie Bennett, Jose Lebron
  • Methods and compositions for diagnosis and treatment of iron misregulation diseases
    Patent number: 6849399
    Abstract: Methods and compositions are provided for the diagnosis and treatment of iron misregulation diseases, including HFE polypeptides, agonists, and antagonists, and transferrin receptor agonists and antagonists.
    Type: Grant
    Filed: August 27, 1997
    Date of Patent: February 1, 2005
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: John N. Feder, Randall C. Schatzman, Zenta Tsuchihashi
  • Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases
    Publication number: 20030073627
    Abstract: Methods and compositions are provided for the diagnosis and treatment of iron overload diseases and iron deficiency diseases.
    Type: Application
    Filed: March 4, 2002
    Publication date: April 17, 2003
    Applicant: Bio-Rad Laboratories, Inc.
    Inventors: John N. Feder, Pamela J. Bjorkman, Randall C. Schatzman
  • Peptides and peptide analogues designed from HFE protein and their uses in the treatment of iron overload diseases
    Publication number: 20020165162
    Abstract: The present invention relates to peptides and peptide analogues designed from HFE protein. In particular, it relates to peptides and peptide analogues designed from an alpha-1 region of HFE protein which lowers the binding affinity of transferrin receptor for transferrin. Such compounds mimic HFE protein function, and reduce iron uptake and/or accumulation by a cell.
    Type: Application
    Filed: July 9, 2001
    Publication date: November 7, 2002
    Applicant: Bio-Rad Laboratories, Inc.
    Inventors: John N. Feder, Randall C. Schatzman, Pamela J. Bjorkman, Melanie Bennett, Jose Lebron
  • Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases
    Patent number: 6391852
    Abstract: Methods and compositions are provided for the diagnosis and treatment of iron overload diseases and iron deficiency diseases.
    Type: Grant
    Filed: June 12, 1998
    Date of Patent: May 21, 2002
    Assignees: Bio-Rad Laboratories, Inc., California Institute of Technology
    Inventors: John N. Feder, Pamela J. Bjorkman, Randall C. Schatzman